Clinical Study Synopsis
|
|
- Scarlett Bates
- 5 years ago
- Views:
Transcription
1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayer.com apply to the contents of this file.
2 Clinical Trial Results Synopsis Study Design Description Study Sponsor: Bayer Yakuhin Co.LTD. Study Number: NCT Study Phase: IV (Prospective Non-Interventional) Official Study Title: Overview of Post-marketing surveillance- Mirena, Japan DUI Therapeutic Area: Women s Healthcare Test Product Name of Test Product: Name of Active Ingredient: Dose and Mode of Administration: Levonorgestrel IUD (Mirena, BAY ) levonorgestrel Mirena was administered through an intrauterine system with a release rate of 20 mcg/24 h. Reference Therapy/Placebo Reference Therapy: Dose and Mode of Administration: Duration of Treatment: Up to 5 years after Mirera insertion Studied period: Date of first subjects first visit: 10-May-2007 Date of last subjects last visit: 25-Jan-2013 Premature Study Suspension / Termination: Substantial Study Protocol Amendments: No substantial amendments Study Centre(s): 55 sites in Japan Methodology: This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of women who are inserted Mirena for intrauterine contraception. The objective of this study is to assess safety and effectiveness of Mirena under real-life practice conditions. A total 550 patients were planned to be recruited and followed for 5 years. Indication/ Main Inclusion Criteria: Study Objectives: Women who are inserted Mirena for intrauterine contraception Overall: The objective of this study is to assess safety and effectiveness of Mirena under real-life practice conditions. Evaluation Criteria: Efficacy (Primary): Pregnancy rate Page 1 of 3
3 Efficacy (Secondary): None Safety: Incidence of adverse drug reactions and serious adverse events in women who are inserted Mirena [ Time Frame: After Mirera insertion, up to 5 years ] Incidence of adverse drug reactions, especially Pelvic inflammatory disease in women who are inserted Mirena [ Time Frame: After Mirera insertion, up to 5 years ] Incidence of adverse drug reactions in subpopulation in a variety of baseline data (such as demographic data, concomitant disease) and duration of Mirena [ Time Frame: After Mirera insertion, up to 5 years ] Statistical Methods: Pharmacokinetics: Released amount of Levonorgestrel Efficacy (Primary): Variables measured were summarized by use of descriptive statistics. Efficacy (Secondary): Safety: Chi-square test and Fisher's exact test were used for the analyses of safety data Number of Subjects: Pharmacokinetics - if applicable: Released amount of Levonorgestrel No. of subjects received treatment:567 No. of Safety analysis set:563 No. of Efficasy analisis set:486 Results Summary Subject Disposition and Baseline Study Results The number of cases collected was 563 (54 investigational sites), all of which were included in the safety analysis, and 486 were included in the efficacy analysis, excluding 77 due to the reasons of "not evaluable for efficacy" and others. The mean age was 39.4 years. Two out of 563 cases were elderly (65 and 78 years old). There was one case with impaired renal function and one case with impaired hepatic function. The duration of the drug placement was at least 5 years in 13 cases, at least 4 years in 127 cases, at least 3 years in 262 cases, at least 2 years in 351 cases and at least one year in 418 cases. Results Summary Efficacy No pregnancy was reported during the investigation among the cases who placed the drug, indicating favorable efficacy in the long-term use. Results Summary Safety Page 2 of 3
4 A total of 574 adverse drug reactions, etc. were reported in 315 cases (55.95%) out of 563 included in the safety analysis. Adverse drug reactions that were not predicted from the "Precaution for use" in the package insert include anemia in 11 cases, ovarian neoplasm in 10 cases, cystitis in 5 cases, abnormal sensation, breast cancer, dizziness, premenstrual syndrome and hypertension in 2 cases each; other adverse drug reactions were observed in one case each. Out of 10 events of ovarian neoplasm classified as the same preferred term (PT), there was only one unknown adverse drug reaction, which was ovarian neoplasm as the lower level term (LLT); the other 9 were known adverse drug reactions classified as ovarian cystoma as the LLT. Therefore, one out of 10 cases was an unknown ovarian neoplasm. "Blood pressure increased" was listed in the other adverse drug reactions of the "Precaution for use" in July 2012; however, severe hypertension was reported as an unknown adverse drug reaction. The incidence of adverse drug reactions was lower than that reported in the clinical trials up to the time of approval filing, which was 88.80% (428/482). With respect to diabetes mellitus, which is listed in the "Careful administration" of the package insert of the drug, there were no notable findings in the Investigation except diabetes mellitus experienced by 3 cases and type 2 diabetes mellitus experienced by one case. As for the precaution statement in the "Warnings and precautions" that women who have no pregnancy history must not use the drug as the first choice for contraception, there were 95 (16.87%) women with no pregnancy history and 52 (9.24%) with pregnancy history but with no delivery history; however, there were no notable safety issues with or without pregnancy history. The "Warnings and precautions" in the package insert state that the drug should not be inserted until 6 weeks postpartum or until involution of the uterus is complete in order to reduce the incidence of perforation and expulsion. No adverse drug reactions were reported in a case who placed the drug within 6 weeks after the last vaginal delivery. In the safety analysis population, pelvic inflammatory disease (PID) was experienced by 4 cases, and adverse drug reactions extensively interpreted as PID were salpingo-oophoritis in 3 cases and cervicitis in one case. These events occurred within 2 years after placement (6 of them occurred within one year). Two of them were assessed as serious and the other 6 were non-serious. One case had the drug removed, and the other 7 continued the placement. Investigation of the demographic or other baseline factors showing statistically significant differences in cases included in the safety analysis for the Drug Use Investigation revealed no issues of concern requiring new measures to ensure the safety. More than half of the major frequently reported adverse drug reactions of the drug occurred within one year after drug use, and also there were no notable issues of concern in the longterm drug use. Results Summary Pharmacokinetics There were no major differences in the drug exposure estimated on the residual amount in the formulation retrieved after removal compared to the data at the time of approval, i.e., initial release rate: 20µg/day, release rate after 5 years: 10µg/day, mean release rate in 5 years: 14µg/day. Conclusion(s) The results of the Investigation led us to conclude that no factors or concerns affecting the safety or efficacy were observed, thus it is not necessary, at the present moment, to take any special measures such as revising the "Precaution for Use". Publication(s): Date Created or Date Last Updated: 29 OCT 2013 Date of Clinical Study Report: 09 APR 2013 Page 3 of 3
5 Appendix to Clinical Study Synopsis Product Identification Information Product Type US Brand/Trade Name(s) Brand/Trade Name(s) ex-us Generic Name Main Product Company Code Drug Mirena Mirena LNG IUS Mirena IUS Levonorgestrel BAY Other Company Code(s) Chemical Description Other Product Aliases Levonorgestrel: (-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en- 20-yn-3-one Date of last Update/Change: 6 May 2011
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationFDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections
More informationWebposting Clinical Trial Results Synopsis
Study Summary This summary information is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This summary information is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationWelcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.
Mirena is the #1 prescribed IUD * in the U.S. Welcome to Mirena The Mirena Handbook: A Personal Guide to Your New Mirena *Intrauterine Device Supported by 2015-2016 SHS data INDICATIONS FOR MIRENA Mirena
More informationApplication for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines
Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationLONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables
LONG-ACTING REVERSIBLE CONTRACEPTION Summary Tables Bridging the Divide: A Project of the Jacobs Institute of Women s Health June 2016 Table 1. Summary of LARC Methods Available Years Since Effective Copper
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationLevosert levonorgestrel 20mcg/24hour intrauterine device
Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationReview of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016
Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016 INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationMedical Eligibility for Contraception Use
Medical Eligibility for Contraception Use DIVISION OF REPRODUCTIVE HEALTH CENTERS FOR DISEASE CONTROL AND PREVENTION 2016 US Medical Eligibility Criteria for Contraceptive Use (US MEC) Purpose To assist
More informationlevonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer
levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationSummary of product characteristics (SmPC)
Summary of product characteristics (SmPC) What is it and what does it contain? An agency of the European Union Table of contents 1.What is the summary of product characteristics (SmPC)? 2.Where SmPC information
More informationWendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa
Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa Objectives Distinguish the different types of IUDs Understand the mechanism of action and selection of candidates
More informationManagement of Emergency Contraception (EC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of Emergency Contraception (EC) The risks and benefits of an IUD or oral EC should be discussed and documented (see appendix). Reasonable measures
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSimplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok
Simplifying Vide Contraception University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Background Objectives At the conclusion of this presentation participants will be able
More informationInternational Federation of Gynecology and Obstetrics
International Federation of Gynecology and Obstetrics THE ROLE OF POST- ABORTION CONTRACEPTION IN PREVENTION OF UNSAFE ABORTION THE ROLE OF POST- ABORTION CONTRACEPTION IN PREVENTION OF UNSAFE ABORTION
More informationTime Topic Speaker Abbreviation
1. Programme Sunday, 4 th November 2018 Time Topic Speaker Abbreviation 08:00 Welcome, distribution materials 08:30 Overview of the Medical Eligibility Criteria (2015), and the Selected Practices Recommendations
More informationSponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationExample CLINICAL GUIDELINES for Postpartum IUD insertion
Example CLINICAL GUIDELINES for Postpartum IUD insertion Postpartum Intrauterine Device Insertion 1.0 Indications: 1.1 Insertion of an intrauterine device (IUD) for long-acting reversible contraception
More informationClinical Study Synopsis for Public Disclosure
Clinical Study Synopsis for Public Disclosure These results are supplied for informational purposes only in the interest of scientific disclosure. The synopsis may include approved and non-approved uses,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationLevitra According to its FDA-approved product labeling (PI), Levitra is indicated for the treatment of erectile dysfunction.
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Fadwa Almanakly Associate Director, Global Regulatory Affairs Bayer
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Policy: Essure Removal Reference Number: CP.MP.131
Clinical Policy: Reference Number: CP.MP.131 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationCoding for the Contraceptive Implant and IUDs
LARC Quick Coding Guide 2018 UPDATE Coding for the Contraceptive Implant and IUDs CORRECT CODING can result in more appropriate compensation for services and devices. To help practices receive appropriate
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationProduct Information. Confidence that lasts
Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationU.S. Medical Eligibility Criteria for Contraceptive Use, 2010
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Division of Reproductive Health Centers for Disease Control and Prevention August 1, 2013 National Center for Chronic Disease Prevention and
More informationCLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN GERIATRICS *)
3CC9a CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN GERIATRICS *) Guideline Title Clinical Investigation of Medicinal Products in Geriatrics*) Legislative basis Directive 75/318/EEC, as amended Date
More informationClincialTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClincialTrials.gov
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationIntrauterine Devices (IUDs): Access for Women in the U.S.
November 2016 Fact Sheet Intrauterine Devices (IUDs): Access for Women in the U.S. Intrauterine devices (IUDs) are one of the most effective forms of reversible contraception. IUDs, along with implants,
More informationthe IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to
your guide to Helping you choose the method of contraception that s best for you IUD IUD the e IUD IU IUD the IUD 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that s put
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationPrescriber Guide for the Letairis REMS Program
LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationCan an iud cause back pain
Can an iud cause back pain 3-11-2016 It can cause your periods to. Some women may also feel lightheaded from the pain. You can have most IUDs placed at any. "Intrauterine Device ( IUD )." Do not use this
More informationFDA Oversight of Nanotechnology Applications in Foods, Food Packaging, and Nutrient Delivery
FDA Oversight of Nanotechnology Applications in Foods, Food Packaging, and Nutrient Delivery Laura M. Tarantino, Ph.D. Office of Food Additive Safety Center for Food Safety and Applied Nutrition (CFSAN)
More informationPUBLIC HEALTH COMMUNINTY BASED SERVICES SERVICE SPECIFICATIONS
PUBLIC HEALTH COMMUNINTY BASED SERVICES SERVICE SPECIFICATIONS Service Specification No: Service: Authority Lead: CBS18-19(03) Provision of intrauterine device (IUD), intrauterine system (IUS) and sub-dermal
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information